

### **REMARKS**

Upon entry of the presently made amendments, claims 78, 80-82 and 88-91 will be pending pending. Claims 1-77, 79 and 83-87 have been canceled without prejudice.

New claim 91 has been added. Support for new claim 91 is found in the specification as filed at least at page 30, line 26.

Claim 78 has been amended to more clearly set forth the class of compounds recited therein. Support for this amendment is found in the specification as filed at least at page 7, line 27 to page 8, line 32 and page 9, lines 25-29.

Claim 80 has been amended to no longer recite that *b* is 2 or 3.

Claim 81 has been amended to no longer recite that *b* is 0.

Claims 88 and 89 have been amended to depend from claim 78.

No new matter has been added. Applicants reserve their right to prosecute the subject matter of any canceled or amended claim or any unclaimed subject matter in one or more divisional, continuation or continuation-in-part applications.

#### **I. The Rejection of Claims 35-41, 47-69 and 86-90 Under 35 U.S.C. § 112, First Paragraph**

The Advisory Action mailed on January 11, 2006 in connection with the above-identified application maintained the rejection of claims 35-41, 47-69, 75-84 and 86-90 under 35 U.S.C. § 112, first paragraph, for allegedly lacking enablement, as made in the Office Action mailed on September 9, 2005 in connection with the above-identified application.

Preliminarily, Applicants note that the pending claims are directed to a focused class of indazole compounds wherein A-R<sub>1</sub> is optionally substituted phenyl and R<sub>2</sub> is 3-triazolyl or 5-tetrazolyl. Applicants have found that compounds within this class have anti-cancer activity. Most notably, Applicants would like to point out that with respect to a particularly active compound in this class (*i.e.*, CC401), three small Phase I clinical trials directed in part to determine optimal biological doses have been completed and a fourth is currently scheduled. The completed trials have included both healthy volunteers and patients with the acute myeloid leukemia, a cancer of tissue and blood. The fact that this indazole has advanced to clinical trial studies is evidenced by the previously submitted peer-reviewed publication Force *et al.*, 2004, "Inhibitors of Protein Kinase Signaling Pathways - Emerging Therapies for Cardiovascular Disease," *Circulation* 109:1196-1205

(“Force”), a courtesy copy enclosed (*see* bottom of table on page 1198). Applicants respectfully submit that the advancement of a representative indazole compound of the class recited in amended claim 89 demonstrates that the treatment of cancer with such compounds by one skilled in the art would not require undue experimentation.<sup>1</sup>

Applicants respectfully submit that further support for the enablement of the treatment of “cancer” with the compounds of amended claim 89 is found in the remaining disclosure of Force. In particular, Force points to numerous kinase inhibitors which are currently in clinical trials for “cancer” and even predicts that due to the early success with agents targeting kinases, in the future, cancers will be defined not only by tumor type and stage but also by the protein kinase activity profile (*i.e.*, which kinases are dysregulated). *See* pages 1197 and 1198 of Force. Applicants respectfully submit that this disclosure demonstrates the acceptance of kinases, such as JNK, as valid targets for cancer therapy.

Thus, in view of the documentation in the literature regarding the nexus between cancer and the JNK pathway, the demonstration that the claimed indazoles are inhibitors of the JNK pathway, and the ongoing cancer clinical trials of an illustrative indazole compound falling within the scope of the pending method of treatment claims, Applicants respectfully submit that the pending claims are enabled and that it is within the means of those skilled in the art to practice the present claims without undue experimentation.

In view of the above-made amendments and remarks, Applicants respectfully submit that the specification enables the pending method of treatment claims and, accordingly, that the rejection under 35 U.S.C. § 112, first paragraph, has been overcome and should be withdrawn.

---

<sup>1</sup> Applicants note that the Federal Circuit has held that a specification is enabling in part because those skilled in the art would know how to conduct a dose response study to determine the appropriate amounts to be used. *Merck & Co., Inc. v. Biocraft Laboratories, Inc.*, 874 F.2d 804, 809 (Fed. Cir. 1989).

**Conclusion**

Applicants respectfully request that the above remarks be entered in the present application file. No fee is believed to be due in connection with this Response other than that due in connection with the Request for Continued Examination and Petition for Extension of Time; however, in the event that any additional fee is due, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Date: February 9, 2005

Respectfully submitted,

*Anthony M. Insogna, Reg. No. 35,203*

by: *Michl J. Bruner, Reg. No. 47,458* 35,203

Anthony M. Insogna

(Reg. No.)

**JONES DAY**

222 East 41st Street


New York, New York 10017

(858) 314-1130

Enclosures

# Circulation

JOURNAL OF THE AMERICAN HEART ASSOCIATION

American Heart  
Association®   
*Learn and Live*™

## **Inhibitors of Protein Kinase Signaling Pathways: Emerging Therapies for Cardiovascular Disease**

Thomas Force, Keisuke Kuida, Mark Namchuk, Keykavous Parang and John M. Kyriakis

*Circulation* 2004;109;1196-1205

DOI: 10.1161/01.CIR.0000118538.21306.A9

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75214

Copyright © 2004 American Heart Association. All rights reserved. Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://circ.ahajournals.org/cgi/content/full/109/10/1196>

Subscriptions: Information about subscribing to *Circulation* is online at  
<http://circ.ahajournals.org/subscriptions/>

Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, 351 West Camden Street, Baltimore, MD 21202-2436. Phone 410-5280-4050. Fax: 410-528-8550. Email: [journalpermissions@lww.com](mailto:journalpermissions@lww.com)

Reprints: Information about reprints can be found online at  
<http://www.lww.com/static/html/reprints.html>

## Inhibitors of Protein Kinase Signaling Pathways Emerging Therapies for Cardiovascular Disease

Thomas Force, MD; Keisuke Kuida, MD; Mark Namchuk, PhD;  
Keykavous Parang, PhD; John M. Kyriakis, PhD

**Abstract**—Protein kinases are enzymes that covalently modify proteins by attaching phosphate groups (from ATP) to serine, threonine, and/or tyrosine residues. In so doing, the functional properties of the protein kinase's substrates are modified. Protein kinases transduce signals from the cell membrane into the interior of the cell. Such signals include not only those arising from ligand–receptor interactions but also environmental perturbations such as when the membrane undergoes mechanical deformation (ie, cell stretch or shear stress). Ultimately, the activation of signaling pathways that use protein kinases often culminates in the reprogramming of gene expression through the direct regulation of transcription factors or through the regulation of mRNA stability or protein translation. Protein kinases regulate most aspects of normal cellular function. The pathophysiological dysfunction of protein kinase signaling pathways underlies the molecular basis of many cancers and of several manifestations of cardiovascular disease, such as hypertrophy and other types of left ventricular remodeling, ischemia/reperfusion injury, angiogenesis, and atherogenesis. Given their roles in such a wide variety of disease states, protein kinases are rapidly becoming extremely attractive targets for drug discovery, probably second only to heterotrimeric G protein–coupled receptors (eg, angiotensin II). Here, we will review the reasons for this explosion in interest in inhibitors of protein kinases and will describe the process of identifying novel drugs directed against kinases. We will specifically focus on disease states for which drug development has proceeded to the point of clinical or advanced preclinical studies. (*Circulation*. 2004;109:1196-1205.)

**Key Words:** drugs ■ kinases ■ pharmacology ■ inhibitors

A consensus is emerging that protein kinase modulators will be effective treatments for a variety of diseases.<sup>1</sup> However, protein kinases were initially thought to be unsuitable drug targets, in large part because of what was perceived to be an unfavorably high degree of structural conservation within key domains of all protein kinases. Because binding of ATP to kinases is essential for kinase activity and properties of the protein kinase ATP-binding pocket were well understood, agents targeting the ATP pocket were the logical first choice for drug development. However, the structural conservation of protein kinase ATP binding sites and the presence of more than 500 protein kinases in the human genome<sup>2</sup> led to the belief that highly selective small-molecule protein kinase inhibitors targeting the ATP pocket would be difficult to generate. As will be discussed below, the development and characterization of inhibitors of the p38 mitogen-activated protein kinases (MAPKs) indicated that this initial belief was misguided. A second argument against targeting protein kinases for drug development was the observation that modulation of a protein kinase could in one system prove

beneficial, while proving deleterious in another. As an extreme example of this, inhibiting a protein kinase required for triggering programmed cell death could reduce ischemia-induced cell death in terminally differentiated cardiomyocytes but might also favor tumor promotion in other organs or cell types. Finally, toxicity with long-term use was a concern. Thus, inhibiting a protein kinase that is dysregulated in one organ in a particular disease state may prove harmful to other systems in which that same protein kinase is not dysregulated but instead serves essential functions. For example, inhibiting the cell-surface HER2 tyrosine kinase receptor with the monoclonal antibody trastuzumab (Herceptin, Genentech) in patients with breast cancers overexpressing that receptor has produced strikingly beneficial results, but it has come at the expense of severe cardiac dysfunction in some women receiving the therapy, suggesting a critical role for this receptor in cardiomyocyte survival.<sup>3</sup>

All of the above concerns being noted, the “proof of principle” of the tremendous therapeutic potential of small-molecule inhibitors of protein kinases came with the discov-

From the Molecular Cardiology Research Institute, Tufts-New England Medical Center and Tufts University School of Medicine, Boston, Mass (T.F., J.M.K.); Vertex Pharmaceuticals, Inc, Cambridge, Mass (K.K., M.N.); and the Department of Biomedical Sciences, University of Rhode Island, Kingston (K.P.).

Drs Namchuk and Kuida are employees of and Dr Force receives financial support for his laboratory from Vertex Pharmaceuticals, Inc, which produces small-molecule inhibitors of protein kinases, are the subject of this article.

Additional material may be found in the Data Supplement with the online-only version of this article at <http://www.circulationaha.org>.

Correspondence to Thomas Force, MD, Molecular Cardiology Research Institute, Tufts-New England Medical Center, 750 Washington St, Box 8486, Boston, MA 02111. E-mail [tforce@tufts-nemc.org](mailto:tforce@tufts-nemc.org)

© 2004 American Heart Association, Inc.

*Circulation* is available at <http://www.circulationaha.org>

DOI: 10.1161/01.CIR.0000118538.21306.A9

ery of imatinib mesylate (Gleevec, STI-571, Novartis), an ATP-competitive small-molecule inhibitor of the tumorigenic fusion protein Bcr-Abl (reviewed by Barnes and Melo<sup>4</sup>) (Table; Figure 1). c-Abl is a nuclear protein tyrosine kinase the biological function of which is unclear (although it may function in sensing the integrity of the genome and promoting programmed cell death). Bcr is a multifunctional cytosolic polypeptide that may play a role in regulating activity of the Rho subfamily of small G proteins. The fusion of Bcr and Abl to produce Bcr-Abl arises from the chromosomal translocation that creates the Philadelphia chromosome. Unlike c-Abl, Bcr-Abl is both cytosolic and nuclear, and because it forms homodimers that cross-phosphorylate and activate one another, Bcr-Abl manifests constitutively active and inappropriately directed Tyr kinase activity. Bcr-Abl is causal in chronic myelogenous leukemia, and treatment with imatinib has been able to induce complete remissions, at least in the early stages of the disease.<sup>4</sup>

Indeed, the cancer field has led the way in spurring on drug development directed both at protein kinases that, like Bcr-Abl, are activated by mutations and lead directly to growth deregulation and at "permissive" protein kinases that, while otherwise normal themselves, serve as essential effectors for mutant, deregulated gene products. The protein kinases MAPK ERK kinase (MEK)1/2, which activate the extracellular signal-regulated kinase (ERK) family of MAPKs (Figure 2), and the mammalian target of rapamycin (mTOR) are 2 such permissive kinases that play roles in cell cycle progression. Inhibitors of these kinases (U0126 and PD184352 [Figure 1] and rapamycin/sirolimus, respectively) are in clinical trials for the treatment of a variety of tumors (Table). In addition, rapamycin/sirolimus is currently used with dramatic success as an immunosuppressant and an inhibitor of in-stent restenosis.<sup>5</sup> Early successes with agents targeting protein kinases have led to the logical conclusion that in the future, cancers will be defined not only by tumor type and stage but also by the protein kinase activity profile (ie, which kinases are dysregulated).<sup>6</sup> It is likely that the same will be true for complex disease states of the cardiovascular system.

### Developing an Inhibitor

A major issue in drug development is the identification of appropriate targets for therapeutic intervention. To identify a protein kinase as a putative therapeutic target, it is not sufficient simply to know whether it is activated (or inhibited) in a specific disease state, because dysregulation can be an irrelevant consequence of the disease rather than a key contributing factor to disease pathology. At the very least, clear genetic or physiological/cell biological data are needed that implicate a protein kinase as an attractive target.

Once a kinase is validated as a potential target for drug development, screening of chemical libraries is performed to identify possible inhibitors. Many large pharmaceutical companies possess enormous chemical libraries consisting of hundreds of thousands of synthetic compounds. The identification of one or more of these as a candidate inhibitor requires a process called high-throughput screening (HTS). (For the interested reader, a more detailed description of the

process of HTS is available on-line and in Reference 7.) A good, robust, and reliable HTS assay can be used to screen >100 000 small molecules in a day. Typical "hit rates" for an unbiased screen might be only 0.1% to 0.3%; therefore, various strategies have been devised to improve hit rates by focusing the screen. Focusing of the library of compounds can be based on the actual crystal structure of the ATP-binding pocket of the kinase or a family member if known (structure-based library design) or on the structure of compounds already known to bind to the ATP pocket if available (ligand-based library design). These virtual screening or molecular modeling approaches to screen more targeted libraries not only can improve the hit rate but also may reduce the duration and expense of primary screens.<sup>7</sup>

Binding of ATP to a protein kinase is essential for the kinase's phosphotransferase activity, and thus, the ATP-binding pocket is the "target" of most inhibitor screens. As was noted above, this idea initially seemed counterintuitive, given the structural conservation of protein kinase ATP-binding sites.<sup>8</sup> However, there is, in fact, enough structural diversity in these sites<sup>8</sup> to predict that selective ATP-competitive inhibitors can be identified. Indeed, contrary to initial concerns, screens of unbiased compound libraries have identified several ATP competitors that function as relatively selective inhibitors.<sup>9,10</sup>


For a protein kinase inhibitor to have a chance of clinical efficacy, it must bind to the target kinase with an extremely high affinity: several orders of magnitude higher than that of ATP, because the inhibitor will be present in concentrations typically in the mid to high nanomolar range, whereas the intracellular concentration of ATP is millimolar. This suggests that any initial "hits" from an HTS will most likely benefit from optimization to improve potency and selectivity. The efficiency of the optimization process is greatly augmented by the abundant x-ray crystallographic information available for kinase families. Thus, the structure-activity relationship of any compound can be correlated with specific molecular interactions of the compound with the kinase active site, and in this way, the structure of the inhibitor can be optimized.<sup>7</sup> When no structure data exist for a specific kinase, knowledge of the structure of another member of the family can often be used to create binding models from which optimized compounds can be synthesized.<sup>7</sup>

The need for an extremely high binding affinity of an inhibitor to the ATP pocket and the relative similarities of ATP pockets across protein kinase families suggest that it may be beneficial to examine protein kinases for determinants in addition to the ATP pocket that might confer additional specificity. Here, the MAPKs provide an excellent example. The ability of different MAPK groups to interact with and then phosphorylate selective intracellular protein substrates is conferred by a specific substrate docking site of the MAPKs, the common docking (CD) domain, that is quite distal from the ATP binding site.<sup>11</sup> The CD motifs of MAPKs bind complementary sites on the corresponding MAPK substrates (and on MAPK regulators) (eg, MEK1 binding to ERK-1 [Figure 2] is mediated by the CD domain). Although there is substantial sequence conservation among MAPK CD domains, the sequence divergence is sufficient to enable

## Selected Inhibitors of Protein Kinases in Clinical Trials

Kinase Target	Agent	Trial (Disease)	Sponsor
Tyrosine kinases			
ABL (c-Kit, PDGFR)	Gleevec (STI-571)	Approved (CML)	Novartis
EGFR	ZD1839 (Iressa)	Approved (lung cancer)	AstraZeneca
	OSI-774	Phase III (cancer)	OSI/Roche/Genentech
	IMC-C225 (mAb)	Phase III (cancer)	ImClone
	ABX-EGF (mAb)	Phase II (cancer)	Abgenix
	MDX-447 (mAb)	Phase I (cancer)	Merck KgaA
	EMD 72000 (mAb)	Phase I (cancer)	Merck KgaA
	Genistein	Phase II (cancer)	NCI
	RH3 (mAb)	Phase II (cancer)	York Medical Bioscience Inc
EGFR, ERB2R	CI1033	Phase II (cancer)	Pfizer
	EKB569	Phase I (cancer)	Wyeth-Ayerst
	GW2016	Phase I (cancer)	GlaxoSmithKline
	PKI166	Phase I (cancer)	Novartis
VEGFR (PDGFR, FGFR)	SU6668	Phase I (cancer)	Pharmacia Corp
PDGFR (FIt-3)	CT53518	Phase I (cancer)	Millennium Pharmaceuticals
VEGFR	SU5416	Phase III (cancer)	Pharmacia Corp
	PTK787/ZK222584	Phase II (cancer)	Novartis/Schering-Plough
VEGFR (EGFR)	ZD6474	Phase II (cancer)	AstraZeneca
VEGFR (PDGFR)	SU011248	Phase II (cancer)	Sugen
NGFR, Trk	CEP-2583	Phase II (cancer)	Cephalon
HER-2/neu	17-AAG	Phase I (cancer)	Kosan
	Trastuzumab (mAb)	Approved (cancer)	Genetech
	2C4 (mAb)	Phase I (cancer)	Genetech
	CP-724,714	Phase I (cancer)	OSI Pharmaceuticals/Pfizer
	MDX-210 (mAb)	Phase I (cancer)	Novartis
Serine/threonine kinases			
PKC, c-Kit, PDGFR	PKC412	Phase II (cancer, retinopathy)	Novartis
PKC	ISIS 3521	Phase III (cancer)	ISIS Pharmaceuticals
	CGP41251	Phase II (cancer)	Novartis
	UCN-01	Phase I/II (cancer)	Kyowa Hakko Kogyo
	Bryostatins-1	Phase I/II (cancer)	Biotek
PKC- $\beta$	Ly333531	Phase I (cancer)	Eli Lilly
		Phase II/III (diabetic neuropathy)	
CDKs	Flavopiridol	Phase II (cancer)	Aventis
	E7070	Phase I (cancer)	EISAI
	BMS-387032	Phase I (cancer)	Bristol-Myers Squibb
	CYC202	Phase I (cancer)	Cyclacel
MEK1/2	PD184352	Phase II (cancer)	Pfizer
	U-0126	Phase I (cancer)	Promega
MLK	CEP-1347	Phase II (neurodegeneration)	Cephalon
RAF	BAY43-9006	Phase II (cancer)	Onyx Pharmaceuticals/Bayer
	ISIS5132	Phase II (cancer)	Isis pharmaceuticals
	L-779,450	Phase II (cancer)	Merck
Ras	ISIS2503	Phase II (cancer)	Isis pharmaceuticals
	SCH66336	Phase II (cancer)	Schering-Plough
	BMS214662	Phase I (cancer)	Bristol-Myers Squibb
	R115777	Phase I/II (cancer)	Johnson & Johnson
mTOR	CCI779	Phase II (cancer)	Wyeth-Ayerst
	RAD001	Phase I (cancer)	Novartis
		Phase II/III (immunosuppressant)	
	Rapamycin	Approved (immunosuppressant)	Wyeth-Ayerst
p38-MAPK	VX702	Phase II (inflammation; ACS)	Vertex Pharmaceuticals
	BIRB796	Phase III (inflammation; RA; Crohn's)	Boehringer Ingelheim
	SCIO-323	Phase I (RA; stroke; diabetes)	Scios, Inc
	SCIO-469	Phase II (RA; Crohn's)	Scios, Inc
PDK1	UCN-01	Phase I/II (cancer)	Kyowa Hakko Kogyo
JNK1-3	CC401	Phase I	Celgene

VEGFR indicates vascular endothelial growth factor receptor; PDGFR, PDGF receptor; FGFR, fibroblast growth factor receptor; CML, chronic myelogenous leukemia; RA, rheumatoid arthritis; and ACS, acute coronary syndromes. Inhibitors are of two types, monoclonal antibodies (mAbs), which are directed at the extracellular domain of various receptor tyrosine kinases, and small-molecule inhibitors.



**Figure 1.** Chemical structures of several small-molecule protein kinase inhibitors referred to in text. These can be divided into inhibitors that are ATP-competitive, including phenylamino pyrimidines (eg, STI-571), pyridinylimidazoles (SB202190, SB203580, and SB239063), anthra-pyrazolones (SP600125), and maleimides (SB415286), and those that are non-ATP-competitive (MEK1/2 inhibitors, U0126, PD184352, and PD98059, which maintain kinases in an inactive state by preventing their phosphorylation by upstream activating kinases such as Raf). BIRB796, a pyrazole urea, is both noncompetitive and competitive (see text).

exquisite MAPK specificity. Of note, the CD domains are quite small ( $\leq 18$  amino acids), contain key acidic residues, and reside on an exposed surface in the MAPK structure, suggesting that these domains could be ideal targets for drug design.<sup>11</sup>

The use of determinants in addition to the ATP pocket combined with optimization based on crystal structure was recently used to optimize the design of a p38-MAPK inhibitor. Crystallography demonstrated that this inhibitor did not target the ATP binding pocket but rather targeted a novel site in the kinase active site that is exposed after a large conformational change that accompanies binding of the inhibitor.<sup>12</sup> Crystallography allowed the compound to be modified to optimize binding to the novel site and also to establish binding in the ATP pocket. This gives the final compound, BIRB796 (Figures 1 and 3), which is currently in clinical trials for various inflammatory disorders (Table), a high degree of potency and selectivity.


Another approach to inhibit MAPK signaling that might reduce toxicity would be to target upstream activators of the MAPKs rather than the MAPKs.<sup>13</sup> For example, c-Jun N-terminal kinase (JNKs) are activated by at least 12 different

MAPK kinase kinases (MAPKKKs) and 2 MAPK kinases (MAPKKs; see legend to Figure 2 for terminology). Because specific MAPKKKs and MAPKKs transduce the activation of JNKs in response to specific stimuli<sup>14</sup> (eg, MAPKK7 but not MAPKK4 is necessary for JNK activation by tumor necrosis factor [TNF]- $\alpha$ ), one could potentially target MAPKK7 specifically with an inhibitor in patients with inflammatory disorders. This would leave JNK activation by other stimuli acting via MAPKK4, and essential cellular functions regulated by JNKs, at least partially intact.

### Potency and Selectivity

Potency and selectivity are critical issues for the eventual effectiveness and safety of any drug. Potency is expressed as the enzymatic  $IC_{50}$  (concentration of drug that inhibits enzyme activity by 50%). However, reported  $IC_{50}$ s must be interpreted with caution, because the  $IC_{50}$  determined for an ATP-competitive inhibitor will vary depending on the concentration of ATP used in the assay and on the  $K_m$  (the affinity of the kinase for ATP).<sup>10</sup> This has been a source of significant confusion in the literature. For example, results from assays of the widely used anthrapyrazolone JNK inhib-





**Figure 2.** ERK cascade. All MAPKs described to date are part of a 3-tiered cascade whereby MAPKs, in this case, ERKs, are activated by upstream kinases (MAPKKs, in this case MEK1/2), which, in turn, are activated by a MAPKKK (in this case Raf-1). Growth factor-induced activation of pathway often leads to cell cycle progression and, in some cases, activation of survival pathways. I/R in brain also leads to ERK activation, but in this case it is deleterious, leading to neuronal death. It is not clear whether Raf-1 is the MAPKKK involved in I/R-induced activation of ERKs in brain. MEK inhibitors discussed in text are shown.

itor SP600125 (Figure 1) with 20  $\mu\text{mol/L}$  ATP initially suggested that SP600125 was a very potent inhibitor with a low  $\text{IC}_{50}$ . However, the results of studies that used assays with more “physiological” concentrations of ATP (100  $\mu\text{mol/L}$ ) recently demonstrated that SP600125 was, in fact, a relatively weak (and also nonselective) inhibitor with a high  $\text{IC}_{50}$ .<sup>10</sup>


Selectivity is a second key consideration in the design of kinase inhibitors. Compounds are “profiled” for their selectivity against panels of kinases (often 30 or more) to determine which targets, aside from the intended one, are being affected. These panels are chosen in a variety of ways but often include specific kinases that one does not want the drug to inhibit and/or a selection of kinases with a great deal of structural diversity at the active site (to broadly screen for nonspecific inhibition). Relative  $\text{IC}_{50}$ s of the drug for the

target kinase versus the others in the panel are then determined. Again, the concentration of ATP used in the assay is critical to allow an accurate comparison to be made. One approach to allow interpretation of relative  $\text{IC}_{50}$ s for an inhibitor between enzymes is to customize the assay conditions for the ATP affinity for each kinase in the screening panel (eg, fix the ATP concentration at the  $K_m$  for each kinase). Alternatively, others recommend using concentrations of ATP,  $\geq 100 \mu\text{mol/L}$ , that are well above the  $K_m$  for all of the kinases in the panel.<sup>10</sup>

What is an acceptable level of selectivity? There is no consensus, but in general, the goal is an  $\text{IC}_{50}$  that is at least 100-fold lower for the target kinase. However, this may vary depending on the indication, and in some cases, one might tolerate (or even prefer) agents that are not entirely selective. For example, in cancer, one might tolerate inhibition of kinases that positively regulate the cell cycle (cyclin-dependent kinases, Cdks) or that are antiapoptotic (eg, Akt) by a drug targeting Bcr-Abl, because antitumor activity might be greater. However, because of enhanced toxicity, one would not tolerate inhibition of Cdks or Akt by a drug targeting p38-MAPK for inflammatory diseases. Similarly, lack of selectivity for drugs that will be used short-term only might not be a major problem.

Once selectivity is determined in kinase assays *in vitro*, the selectivity profile is then determined in a cellular system. Given that cellular ATP concentrations are typically in the millimolar range, an upward shift in the cellular  $\text{IC}_{50}$  versus the enzymatic  $\text{IC}_{50}$  (performed at 100  $\mu\text{mol/L}$  or less) is often observed. The magnitude of this shift is dictated by a number of factors, including the ATP  $K_m$  for the target enzyme, the cellular permeability of the drug, and the amount of inhibition of the target kinase required to elicit the cellular response being monitored (eg, 20% inhibition of a particular kinase may be sufficient to lead to complete inhibition of a biological response). An effective general counterscreening strategy is to obtain enzymatic  $\text{IC}_{50}$  values for an extensive panel of biochemical kinase assays, then assess the cellular consequences of the observed inhibition pattern in cellular readouts biased to respond to inhibition of the signaling pathways represented in the enzymatic panel. If a drug with borderline selectivity in enzymatic assays has excellent characteristics in the cell-based assays (good inhibition of the target pathway, limited inhibition of other pathways, and no toxicity), the borderline enzymatic selectivity may be deemed adequate.

Finally, although the  $\text{IC}_{50}$  and selectivity studies (determined in assays *in vitro*) usually predict activity in the cell, this is not always the case. Thus, a compound with apparent high activity and specificity *in vitro* may display markedly different and even unexpectedly nonspecific activity *in vivo*. For example, the pyridinyl imidazoles SB203580 and SB202190 (Figure 1), which inhibit p38 MAPKs, are remarkably specific when assayed *in vitro* for inhibition of a variety of protein kinases.<sup>9</sup> The basis for this specificity was revealed in the crystal structure of p38 $\alpha$  complexed with SB203580. To accommodate a fluorophenyl moiety present in the SB203580 structure, the amino acid at position 106 of the



**Figure 3.** Mechanisms of p38-MAPK-induced cardiomyocyte death. I/R activates p38-MAPK, leading to both cytokine (and chemokine) production and upregulation of adhesion molecules on endothelial cells. This leads to leukocyte infiltration into ischemic region. Certain cytokines (eg,  $\text{TNF-}\alpha$ ) are directly cytotoxic to cardiomyocytes. In addition, p38-MAPK probably also directly activates cell death pathways in ischemic cardiomyocytes (ie, cytokine- and leukocyte-independent effects on cell death). p38-MAPK inhibitors discussed in text are shown. Of note, JNKs also act to stabilize cytokine mRNA and, in addition, activate intrinsic cell death pathway by inducing release of cytochrome c from mitochondria.<sup>36</sup> This suggests that JNK inhibitors may also be protective against I/R injury (see text).

kinase must be no larger than Thr.<sup>15</sup> c-Raf, a protein kinase that activates the ERKs, is downstream of many growth factor receptors and plays a role in inducing cell-cycle progression (Figure 2), has a Thr (Thr321) at a site corresponding to Thr106 of p38 $\alpha$ . Not unexpectedly, therefore, c-Raf is inhibited by SB203580 and SB202092 in vitro, albeit at concentrations at least an order of magnitude higher than that needed to inhibit p38 $\alpha$ .<sup>13,14</sup> However, in cell-based assays, the Raf-Mek-ERK pathway is not inhibited by SB203580 or SB202092. Surprisingly, SB203580 and SB202092 trigger a striking activation of c-Raf in vivo.<sup>16</sup> Similarly, ZM336372 (Figure 1), a novel phenylamido derivative, is an in vitro Raf (and p38-MAPK) inhibitor but is a potent activator of c-Raf in intact cells. The basis for these paradoxical findings is unknown, but they are indicative of the fact that assertions as to the specificity of a compound in vitro require rigorous and comprehensive testing in cellular and whole-animal systems.

### To the Bedside

The Table is a listing of most of the protein kinase inhibitors currently in clinical trials and the diseases targeted. As can be seen, most are cancer trials, but there is a trend toward targeting protein kinases for the treatment of a number of chronic conditions other than cancer, including inflammatory and cardiovascular diseases. Indeed, several of the agents listed in the Table have strong preclinical data suggesting that they may be efficacious in the therapy of patients with a variety of cardiovascular diseases. The list of potential protein kinase targets for cardiovascular therapies is extensive. However, rather than a summary of disease states and protein kinases possibly involved (an excellent review taking this approach for heart failure was recently published<sup>17</sup>), we will discuss a few disease states for which inhibitors exist that are either already in the earliest stages of clinical trials or are in the late stages of preclinical development. These examples, we hope, will illustrate that what was once perceived to be impractical now seems reasonable and attainable.

### Acute Coronary Syndromes

Two families of stress-activated MAPKs, the JNKs and p38-MAPKs, are activated by ischemia/reperfusion (I/R).<sup>14,18</sup> and there is some indication that inhibition of either the JNKs or p38s might prove beneficial for treating acute coronary syndromes (ACS). However, validating these MAPKs as targets in ACS, that is, whether activation of the kinases is beneficial or detrimental, has been difficult.<sup>19</sup> This is because of the lack of good genetic models (ie, mice deleted for the gene) and, until recently for p38, good inhibitors with which to address the question in vivo. Two members of the p38 MAPK family, p38 $\alpha$  and p38 $\beta$ , are activated by ischemia. The first effective inhibitor of p38 $\alpha/\beta$  was discovered by Lee and coworkers<sup>20</sup> at SKF in a broad-based screen for "cytokine-suppressive antiinflammatory drugs" based on their ability to inhibit endotoxin-induced cytokine production by macrophages in culture. The target of this drug was later identified to be the p38s. Because it seems clear that the first wave of drugs targeting kinase pathways to be used in patients will be dominated by p38-MAPK inhibitors, we will

describe these kinases and the mechanisms by which the inhibitors work in some detail.

Preventing the release of inflammatory cytokines and chemokines represents a potentially promising approach to treating ACS (Figure 3) and, possibly, the development and progression of atherosclerotic plaques. Indeed, a p38 inhibitor, VX702, is currently in a phase II clinical trial in patients presenting with ACS. The half-life of the mRNA for many cytokines (and growth factors) is extremely short, allowing for rapid downregulation of expression when the inciting stimulus is removed. This short half-life is largely a result of the presence of AU-rich elements (AREs, consisting of several copies of the sequence AUUUA) in the 3'-untranslated region of the mRNA.<sup>21</sup> ARE-binding proteins (ARE-BPs) bind to the AREs, and most ARE-BPs target mRNA for degradation. When activated, p38s phosphorylate ARE-BPs, inhibiting their activity.<sup>21</sup> The end result is p38-dependent stabilization of the cytokine mRNA, leading to increased production of the cytokine protein and activation of inflammatory cells and of endothelial cells, the latter leading to upregulation of adhesion molecules. Thus, p38 inhibitors block phosphorylation of the ARE-BPs, leading to degradation of the cytokine mRNAs, including those coding for TNF- $\alpha$ , interleukin (IL)-1 $\alpha/\beta$ , IL-6, IL-10, interferon (IFN)- $\gamma$ , MIP1 $\alpha/\beta$ , and IL-8. Although stabilization of cytokine mRNA has obviously been an important response to infection over millions of years of evolution, inappropriate activation of inflammatory responses has, over the past 100 years, become a significant factor driving the explosion in the prevalence of a number of chronic disease states.

Several companies have developed p38 inhibitors, and some of these have demonstrated efficacy in models of inflammatory diseases, including inflammatory arthritides and inflammatory bowel disease, as well as in endotoxemia.<sup>22,23</sup> Some of these inhibitors are currently in clinical trials for rheumatoid arthritis and Crohn's disease (Table). With the rationales that (1) ACSs, including myocardial infarction, had prominent inflammatory components and (2) p38 activation in ischemic tissue might, independent of effects on inflammatory responses, have detrimental effects on cardiomyocyte survival (see Reference 17 and references therein), the efficacy of these drugs was tested in animal models of acute myocardial infarction.

Early-generation p38 inhibitors, SB203580 and SB242710, reduced I/R-induced apoptosis and preserved cardiac function in a Langendorff-perfused rabbit heart model (reviewed in Reference 20). Because with this model, the heart is perfused with a buffer and therefore there are no leukocytes in the perfusate, the findings suggest that p38 inhibition has beneficial effects directly on the myocardium, in addition to its known effects on leukocyte recruitment and activation (Figure 3). This leukocyte-independent protective effect of p38 inhibition on the myocardium probably involves inhibition of I/R-induced production of cytotoxic cytokines by the heart and inhibition of p38-dependent proapoptotic pathways in cardiomyocytes. More recently, a newer-generation p38 inhibitor, SB239063<sup>24</sup> (Figure 1), that can readily be used in vivo has demonstrated beneficial effects in the intact rat model of I/R injury. In addition to direct protective effects of

p38 on cardiomyocyte survival, SB239063 produced a dramatic reduction in the myocardial inflammatory response, as evidenced by reduced upregulation of P-selectin and intercellular adhesion molecule and reduced neutrophil accumulation within the ischemic zone. Other related potential applications of p38 inhibitors include preservation of mechanical function of cold-stored hearts before transplantation.<sup>25</sup> This effect of p38 inhibition may be, in part, related to increased contractility caused by enhanced myofilament responsiveness to calcium.<sup>26</sup>

There are other potential applications for these cytokine-suppressive drugs, including the treatment of patients with heart failure. Although the RENEWAL and ATTACH trials,<sup>27</sup> targeting TNF- $\alpha$  by "capturing" it with a monoclonal antibody or a soluble receptor, produced negative results and raised concerns over worsening of heart failure, this of course does not necessarily mean that the concept of anticytokine therapies in heart failure is invalid, and it is conceivable that more broad-based anticytokine therapy, such as one achieves with p38 inhibitors, could be beneficial. Furthermore, we could benefit from the experiences of the oncologists that demonstrate that one may need to define the molecular phenotype or kinase activity profile of the individual patient, because just as with cancer, patients with the clinical diagnosis of "heart failure" are bound to have very different profiles (as evidenced by the lack of consensus on the signaling abnormalities present in the failing heart<sup>17</sup>). Although it is difficult, failing to do so may lead to discarding agents that are effective in subsets of patients. As an example, trastuzumab, the anti-HER2 tyrosine kinase receptor antibody, which confers a 22.5% improvement in overall survival in breast cancer patients with tumors that overexpress HER2 (25% to 30% of all breast cancers), would have been found to be of no value if it had been initially tested in breast cancer patients irrespective of the HER2 status.<sup>6</sup>

Other potential concerns with anticytokine therapies include a possible increased risk of infection, including reactivation of tuberculosis, and the development of opportunistic infections that have been seen with the anti-TNF therapies and with anakinra, an IL-1 receptor antagonist.<sup>28</sup> Of course, whether these issues are specific to the anti-TNF and anti-IL-1 therapies used or will be a general feature of all anticytokine therapies remains to be determined.

### **Stroke**

Inhibition of several protein kinase pathways has been shown to be beneficial in animal models of stroke. These include the 3 families of MAPKs, the ERKs, JNKs, and p38 MAPKs.<sup>14</sup> In addition, cell culture studies suggest that inhibitors of glycogen synthase kinase-3 (GSK-3) may also be protective.<sup>29,30</sup> The first reports of neuroprotection in vivo with a kinase inhibitor used direct injection into the cerebral ventricles of PD98059 (Figures 1 and 2), a first-generation inhibitor of the activation of MEK1/2<sup>9</sup> (Figure 2 legend), the kinases that activate the ERKs.<sup>31</sup> This was followed by studies with intravenous administration of another MEK1/2 inhibitor, U0126 (currently in clinical trials for cancer; Table), which was also protective against forebrain and focal cerebral ischemia.<sup>32</sup> Remarkably, beneficial effects were seen with

administration after 3 hours of ischemia, before reperfusion. These studies seemed counterintuitive, because the ERKs had generally been thought to be antiapoptotic in most settings (Figure 2), including in I/R injury in the heart.<sup>19</sup> The mechanism of protection may be prevention of excitotoxicity,<sup>33</sup> which is neuronal death caused by release of excitatory amino acids that activate metabotropic glutamate receptors. Excitotoxicity plays a critical role in I/R injury in the brain, and although the precise mechanisms of protection remain to be determined, MEK1/2 inhibitors may be blocking release of glutamate. In addition to stroke, MEK1/2 inhibitors have been reported to be protective against traumatic brain injury.<sup>34</sup> As one caveat, PD98059 and U0126 also block activation of MEK5,<sup>9</sup> the kinase that activates ERK5, the sole member of the fourth MAPK family. Thus, one cannot at this time formally rule out MEK5/ERK5 as the relevant target. Strikingly, another MEK1/2 inhibitor, PD184352, has been reasonably well tolerated when administered orally, twice daily, for 21 days (repeating every 4 weeks) in a phase I dose-ranging trial in cancer patients, with only fatigue, rash, and diarrhea being commonly reported.<sup>6</sup>

Inactivation of JNK3 (via gene deletion in a knockout mouse), which is selectively expressed in the central nervous system, and inhibition of p38 activation (by SB239063) were also protective in stroke models.<sup>35,36</sup> In the latter case, SB239063 reduced stroke-induced expression of TNF- $\alpha$  and IL-1 $\beta$ , cytokines that are believed to enhance neuronal loss after I/R. No fewer than 8 companies have reported the development of JNK inhibitors, many focusing on JNK3 and neuroprotection (stroke and neurodegenerative disorders).<sup>37</sup> Some have reported enhanced cell survival in a stroke model.<sup>37</sup> Safety studies with one agent (CC401, Table) are ongoing in healthy volunteers.<sup>37</sup>

Inhibitors of GSK-3 are being proposed as potential therapies for disorders as diverse as bipolar mood disorders (lithium and valproic acid are GSK-3 inhibitors), Alzheimer's disease (in which GSK-3 is believed to play a key role in formation of the neurofibrillary tangles and amyloid plaques, the latter being reduced by lithium in an animal model of Alzheimer's disease<sup>38</sup>), and stroke.<sup>30</sup> GSK-3 is inhibited when phosphorylated by the antiapoptotic kinase Akt, and at least part of the antiapoptotic effects of Akt are believed to be mediated by inhibition of GSK-3. GSK-3 inhibition may also mediate part of the phenomenon of ischemic preconditioning.<sup>39</sup> Published data are limited, but at this point, selective inhibitors (SB216763 and SB415286; Figure 1) have been shown to block neuronal cell death in culture induced by pharmacological inhibition of the PI3-kinase/Akt pathway or by polyglutamine toxicity caused by the Huntington's disease mutation.<sup>29,40</sup> Although promising, this kinase is a critical regulator of many basic cellular processes, including development, cardiac growth and hypertrophy, and tumorigenesis.<sup>41,42</sup> Therefore, it is likely that in the near future, inhibitors of GSK-3 will be restricted to relatively short-term use in high-risk patients.

### **Hypertension**

Rho belongs to a family of small GTP-binding proteins that mediate intracellular signaling induced by activation of het-

erotrimeric G protein-coupled receptors and growth factor receptors. In the cardiovascular system, Rho regulates vascular smooth muscle contraction by modulating sensitivity to  $\text{Ca}^{2+}$ . One Rho effector is Rho kinase (ROCK), of which 2 isoforms have been identified. ROCKs phosphorylate the myosin-binding subunit of myosin light chain phosphatase and LIM kinase, ultimately regulating phosphorylation of myosin light chain and, via this mechanism, vascular smooth muscle cell contraction.<sup>43</sup> Therefore, it is tempting to speculate that ROCK inhibition could enhance coronary vasodilation by changing  $\text{Ca}^{2+}$  sensitivity of coronary artery smooth muscle cells. In fact, a ROCK inhibitor, hydroxyfasudil, suppresses myosin light chain phosphorylation and significantly inhibits coronary spasm in a pig model. Two recent clinical trials of fasudil indicate that it may be an effective and well-tolerated antianginal agent<sup>44</sup> and also may be of benefit in patients with microvascular spasm of the coronary arteries.<sup>45</sup> Although the selectivity of fasudil against ROCKs is in question, these results suggest a potential use of ROCK inhibitors as novel agents to treat symptomatic patients with CAD. Another relatively specific ROCK inhibitor, Y-27632 (Figure 1),<sup>9</sup> is effective in lowering systolic blood pressure in spontaneously hypertensive rats, DOCA-salt rats, and renal hypertensive rats without affecting blood pressure in normal rats.<sup>43</sup> Collectively, selective ROCK inhibitors will probably be a novel approach to the treatment of hypertension. However, Y-27632 has also been shown to affect metastasis, neurite outgrowth, and contraction of smooth muscle cells other than vascular smooth muscle cells.<sup>43</sup> Therefore, the safety of Y-27632 and related agents remains a question and will need to be carefully evaluated in clinical trials.

Given the difficulty in controlling hypertension in elderly patients and diabetics, there will probably be many more targets against which inhibitors will be made. These could include the WNK (with no lysine) family of kinases, mutations of which are responsible for a rare hereditary form of hypertension, pseudohypoaldosteronism type II.<sup>46</sup> Because the WNK4 gene lies close to a locus showing the strongest linkage to blood pressure variation in the Framingham Heart Study, less severe mutations and polymorphisms of the WNK genes may play a more general role in hypertension. If so, these kinases might be ideal targets.

#### **Diabetes and the Metabolic Syndrome**

Another avenue open to manipulating activity of protein kinases is to identify drugs that activate, as opposed to inhibiting, a kinase. Protein kinases that are beneficially activated by allosteric mechanisms represent attractive targets for such therapies. One of these is the 5'-AMP-activated protein kinase (AMPK). AMPK exists in the cell as a heterotrimer of  $\alpha$ ,  $\beta$ , and  $\gamma$  subunits (the  $\alpha$  subunit containing the kinase domain). Genetic mutations in the human  $\gamma$ 2 subunit of AMPK have been linked to hypertrophic cardiomyopathy and to ventricular preexcitation.<sup>47</sup> Specifically, these mutations are associated with a metabolic storage disorder marked by the accumulation of excess glycogen granules in the myocardium. Although the mechanisms by which these mutations lead to cardiomyopathy and preexcitation are not entirely clear, the mutations appear to inhibit

activation of AMPK by AMP. Because AMPK inhibits glycogen synthase, the mutation could lead to increased glycogen synthase activity, increased glycogen production, and the observed accumulation of glycogen in the heart.

The reason that AMPK has generated a tremendous amount of interest on the part of pharmaceutical companies, however, is that activators of it could be useful in the treatment of patients with metabolic syndrome, diabetes, or hyperlipidemia.<sup>48</sup> AMPK was initially discovered in the early 1970s as an AMP-dependent kinase that inactivated HMG-CoA reductase and acetyl-CoA carboxylase (ACC).<sup>49</sup> It has since been established that AMPK functions as a cellular "fuel sensor" that is activated in times of reduced energy availability (when [AMP] is relatively high) and serves to inhibit anabolic processes (lipogenesis) and enhance glucose uptake.<sup>49</sup>

Several compelling lines of evidence point to the potential of AMPK as a useful drug target. ACC, the rate-limiting enzyme in fatty acid synthesis, catalyzes the formation of malonyl-CoA, a potent inhibitor of fatty acid oxidation. By inhibiting ACC, AMPK elevates fat oxidation.<sup>49</sup> In addition, AMPK activation leads to reduced levels of hepatic sterol response element-binding protein-1 and consequently suppresses the expression of several lipogenic genes. Thus, therapeutic activators of AMPK could reduce serum triglycerides. As an inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, AMPK also functions to block cholesterol production,<sup>49</sup> and therapeutic AMPK activators could serve in a manner similar to the statins. In addition, AMPK is activated in exercise, triggering skeletal muscle glucose uptake in an insulin-independent manner. Of particular note, pharmacological activation of AMPK with 5-aminoimidazole-4-carboxamide 1- $\beta$ -D-ribofuranoside (AICAR) mimics exercise and triggers insulin-independent skeletal muscle glucose uptake. Thus, AMPK activators could also alleviate glucose intolerance. In support of this, the biguanide antidiabetic metformin may exert its effects in part by activating AMPK.<sup>48</sup>

The ability to activate AMPK in vitro with AMP and in vivo with AICAR (which is phosphorylated in the cell to ZMP, an analogue of AMP) and the observed antilipogenic and glucose transport effects of AICAR indicate that drugs targeting AMPK will need to be AMPK activators. It is likely that AMP-like compounds will provide the richest source of potential AMPK pharmaceuticals. Identification of such compounds will be assisted by the elucidation of the structural features of the AMPK AMP-binding pocket.

#### **Conclusions**

It is very likely that the next several years of translational cardiovascular research will feature a number of clinical trials using inhibitors of protein kinase signaling pathways to treat a variety of disorders. We have touched on some of the targets for which development of inhibitors is more advanced, but there are many others with great potential, including the  $\beta$ -adrenergic receptor kinase (heart failure)<sup>50</sup> and some kinase inhibitors that are currently in clinical trials for cancer and are in the discovery phase for atherosclerosis and restenosis (eg, growth factor receptors, including the platelet-derived growth

factor receptor, cell cycle regulators such as Cdk-1/-2, and protein kinase C) and for stroke (eg, Cdk).<sup>51</sup> Toxicity remains a major concern, because many of these kinases not only play roles in the pathogenesis of diseases but also function in pathways that regulate the most basic of normal cellular processes. That said, preclinical data have been reassuring. Toxicity data from clinical trials of these agents in cancer will be illustrative, but many of these studies have been designed to identify, or have used, the "maximum tolerated dose," which may be significantly higher than the doses that will be used in cardiovascular diseases. The use of combination therapy, targeting 2 or more kinases on the same or parallel pathways, may allow the use of lower (and therefore less toxic) doses and has shown some promise in cancer trials.<sup>6</sup> However, the majority of early trials will focus on individual kinases and their role in diseases for which only short-term therapy will be needed (eg, ACS or stroke) or for which targeted local delivery is possible. It must be realized, however, that these may not necessarily be the disease states most likely to benefit from therapy. Finally, as highlighted above, given the vast numbers of protein kinases in the human genome and their sequence and structural similarities, added to the inability to test the drugs against all kinases, specificity will remain a concern with these agents. Despite these obstacles, this new class of agents offers a great deal of promise to expand our therapeutic options for a wide variety of cardiovascular diseases.

### Acknowledgments

This work was supported by US Public Health Service grants HL-61688 and HL-67371 to Dr Force, GM-46577 and DK-41513 to Dr Kyriakis, and a Basic Science Grant from the Arthritis Foundation to Dr Kyriakis. The authors thank Chris Vlahos for invaluable discussions. We sincerely apologize to those whose work could not be cited because of space limitations.

### References

- Cohen P. Protein kinases: the major drug targets of the twenty-first century? *Nat Rev Drug Disc.* 2002;1:309–315.
- Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. *Science.* 2002;298:1912–1934.
- Slaman DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med.* 2001;344:783–792.
- Barnes DJ, Melo JV. Management of chronic myeloid leukemia: targets for molecular therapy. *Semin Hematol.* 2003;40:34–49.
- Marx SO, Marks AR. Bench to Bedside: The development of rapamycin and its application to stent restenosis. *Circulation.* 2001;104:852–855.
- Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. *Nat Rev Drug Disc.* 2003;2:296–313.
- Walters WP, Namchuk M. Designing screens: how to make your hits a hit. *Nat Rev Drug Disc.* 2003;2:259–266.
- Huse M, Kuriyan J. The conformational plasticity of protein kinases. *Cell.* 2002;109:275–282.
- Davies SP, Reddy H, Caivano M, et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. *Biochem J.* 2000;351:95–105.
- Bain J, McLauchlan H, Elliott M, et al. The specificities of protein kinase inhibitors: an update. *Biochem J.* 2003;371:199–204.
- Tanoue T, Nishida E. Docking interactions in the mitogen-activated protein kinase cascades. *Pharmacol Ther.* 2002;93:193–202.
- Pargellis C, Tong L, Churchill L, et al. Inhibition of p38 MAP kinase utilizing a novel allosteric binding site. *Nat Struct Biol.* 2002;9:268–272.
- Harper SJ, LoGrasso P. Inhibitors of the JNK signaling pathway. *Drugs Future.* 2001;26:957–973.
- Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. *Physiol Rev.* 2001;81:807–869.
- Gum RJ, McLaughlin MM, Kumar S, et al. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB203580, by alteration of one or more amino acids within the ATP binding pocket. *J Biol Chem.* 1998;273:15605–15610.
- Hall-Jackson CA, Goedert M, Hedge P, et al. Effect of SB203580 on the activity of c-Raf in vitro and in vivo. *Oncogene.* 1999;18:2047–2054.
- Vlahos CJ, McDowell SA, Clerk A. Kinases as therapeutic targets for heart failure. *Nat Rev Drug Disc.* 2003;2:99–113.
- Pombo CP, Bonventre JV, Avruch J, et al. The stress-activated protein kinases (SAPKs) are major c-Jun amino-terminal kinases activated by ischemia and reperfusion. *J Biol Chem.* 1994;269:26546–26551.
- Abe J, Baines CP, Berk BC. Role of mitogen-activated protein kinases in ischemia and reperfusion injury: the good and the bad. *Circ Res.* 2000;86:607–609.
- Lee JC, Kumar S, Griswold DE, et al. Inhibition of p38 MAP kinase as a therapeutic strategy. *Immunopharmacology.* 2000;47:185–201.
- Frevel AE, Bakheet T, Silva AM, et al. p38 mitogen-activated protein kinase-dependent and -independent signaling of mRNA stability of AU-rich element-containing transcripts. *Mol Cell Biol.* 2003;23:425–436.
- Andreaskos E. Targeting cytokines in autoimmunity: new approaches, new promise. *Expert Opin Biol Ther.* 2003;3:435–447.
- Branger J, van den Blink B, Weijer S, et al. Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. *Blood.* 2003;101:4446–4448.
- Gao F, Yue T-L, Shi D-W, et al. p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation. *Cardiovasc Res.* 2002;53:414–422.
- Clanachan AS, Jaswal JS, Gandhi M, et al. Effects of inhibition of myocardial extracellular-responsive kinase and p38 mitogen-activated protein kinase on mechanical function of rat hearts after prolonged hypothermic ischemia. *Transplantation.* 2003;75:173–180.
- Liao P, Wang SQ, Wang S, et al. p38 mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes. *Circ Res.* 2002;90:190–196.
- Coletta AP, Clark AL, Banarjee P, et al. Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. *Eur J Heart Failure.* 2002;4:559–561.
- Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. *J Rheumatol Suppl.* 2002;65:33–38.
- Cross DA, Culbert AA, Chalmers KA, et al. Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. *J Neurochem.* 2001;77:94–102.
- Eldar-Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. *Trends Mol Med.* 2002;8:126–132.
- Alessandrini A, Namura S, Moskowitz MA, et al. Inhibition of MEK1 protects against damage resulting from focal cerebral ischemia. *Proc Natl Acad Sci U S A.* 1999;96:12866–12869.
- Namura S, Iihara K, Takami S, et al. Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia. *Proc Natl Acad Sci U S A.* 2001;98:11569–11574.
- Murray B, Alessandrini A, Cole AJ, et al. Inhibition of the p44/p42 MAP kinase pathway protects hippocampal neurons in a cell-culture model of seizure activity. *Proc Natl Acad Sci U S A.* 1998;95:11975–11980.
- Mori T, Wang X, Jung JC, et al. Mitogen-activated protein kinase inhibition in traumatic brain injury: in vitro and in vivo effects. *J Cereb Blood Flow Metab.* 2002;22:444–452.
- Yang DD, Kuan CY, Whitmarsh AJ, et al. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. *Nature.* 1997;389:865–870.
- Barone FC, Irving EA, Ray AM, et al. Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia. *Med Res Rev.* 2001;21:129–145.
- Manning AM, Davis RJ. Targeting JNK for therapeutic benefit: from junk to gold? *Nat Rev Drug Disc.* 2003;2:554–565.
- Phiel CJ, Wilson CA, Lee VM-Y, et al. GSK-3 $\alpha$  regulates production of Alzheimer's disease amyloid- $\beta$  peptides. *Nature.* 2003;423:435–439.
- Tong H, Imahashi K, Steenbergen C, et al. Phosphorylation of glycogen synthase kinase-3 $\beta$  during preconditioning through a phosphatidylinositol-3-kinase-dependent pathway is cardioprotective. *Circ Res.* 2002;90:377–379.

40. Carmichael J, Sugars KL, Bao YP, et al. Glycogen synthase kinase-3 $\beta$  inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. *J Biol Chem*. 2002;277:33791–33798.
41. Haq S, Michael A, Andreucci M, et al. Stabilization of  $\beta$ -catenin by a Wnt-independent mechanism regulates cardiomyocyte growth. *Proc Natl Acad Sci U S A*. 2003;100:4610–4615.
42. Hardt SE, Sadoshima J. Glycogen synthase kinase-3 $\beta$ : a novel regulator of cardiac hypertrophy and development. *Circ Res*. 2002;90:1055–1063.
43. Narumiya S, Ishizaki T, Uehata M. Use and properties of ROCK-specific inhibitor Y-27632. *Methods Enzymol*. 2000;325:273–284.
44. Shimokawa H, Hiramori K, Iinuma H, et al. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. *J Cardiovasc Pharmacol*. 2002;40:751–761.
45. Mohri M, Shimokawa H, Hirakawa Y, et al. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. *J Am Coll Cardiol*. 2003;41:15–19.
46. Wilson FH, Disse-Nicodeme S, Choate KA, et al. Human hypertension caused by mutations in WNK kinases. *Science*. 2001;293:1107–1112.
47. Blair E, Redwood C, Ashrafian H, et al. Mutations in the  $\gamma$ 2 subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. *Hum Mol Genet*. 2001;10:1215–1220.
48. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. *Nature*. 2001;414:356–359.
49. Hardie DG, Carling D, Carlson M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? *Annu Rev Biochem*. 1998;67:821–855.
50. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. *Nature*. 2002;415:206–212.
51. Knockaert M, Greengard P, Meijer L. Pharmacologic inhibitors of cyclin-dependent kinases. *Trends Pharmacol Sci*. 2002;23:417–425.